Fennec Pharmaceuticals Inc. (TSE:FRX) Director Rostislav Christov Raykov Sells 7,569 Shares

Fennec Pharmaceuticals Inc. (TSE:FRX) Director Rostislav Christov Raykov sold 7,569 shares of the stock in a transaction on Wednesday, March 5th. The shares were sold at an average price of C$9.71, for a total transaction of C$73,503.54.

Rostislav Christov Raykov also recently made the following trade(s):

• On Wednesday, February 5th, Rostislav Christov Raykov sold 2,431 shares of Fennec Pharmaceuticals stock. The shares were sold at an average price of C$9.66, for a total transaction of C$23,476.17.
• On Monday, January 6th, Rostislav Christov Raykov sold 10,000 shares of Fennec Pharmaceuticals stock. The shares were sold at an average price of C$8.76, for a total value of C$87,552.00.
• On Friday, December 20th, Rostislav Christov Raykov acquired 25,000 shares of Fennec Pharmaceuticals stock. The shares were purchased at an average price of C$3.87 per share, for a total transaction of C$96,840.00.

Fennec Pharmaceuticals Price Performance

TSE:FRX traded down C$0.26 during mid-day trading on Thursday, hitting C$9.43. The company’s stock had a trading volume of 178 shares, compared to its average volume of 1,596. The company has a current ratio of 7.80, a quick ratio of 10.17 and a debt-to-equity ratio of -620.83. The stock has a fifty day moving average of C$9.16 and a 200-day moving average of C$7.86. The company has a market capitalization of C$181.85 million, a price-to-earnings ratio of -159.74 and a beta of 0.25. Fennec Pharmaceuticals Inc. has a fifty-two week low of C$5.65 and a fifty-two week high of C$15.20.

Analysts Set New Price Targets

Separately, Stephens upgraded shares of Fennec Pharmaceuticals to a “strong-buy” rating in a research note on Monday, November 18th.

Fennec Pharmaceuticals Company Profile

Fennec Pharmaceuticals Inc operates as a biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. It sells its products through regional pediatric oncology specialists and medical science liaisons.